

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/39960 A2

(51) International Patent Classification⁷: **A61K 7/00**

(21) International Application Number: **PCT/EP01/12732**

(22) International Filing Date:
2 November 2001 (02.11.2001)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0027769.9 14 November 2000 (14.11.2000) **GB**

(71) Applicant (for AE, AG, AU, BB, BZ, CA, CY, GB, GD, GH, GM, IE, IL, KE, LC, LK, LS, MN, MW, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW only): **UNILEVER PLC** [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB).

(71) Applicant (for AL, AM, AT, AZ, BA, BE, BF, BG, BJ, BR, BY, CF, CG, CH, CI, CM, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GA, GE, GN, GQ, GR, GW, HR, HU, ID, IS, IT, JP, KG, KP, KR, KZ, LR, LT, LU, LV, MA, MC, MD, MG, MK, ML, MR, MX, MZ, NE, NL, NO, PH, PL, PT, RO, RU, SE, SI, SK, SN, TD, TG, TJ, TM, TR, UA, UZ, VN, YU only): **UNILEVER NV** [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).

(71) Applicant (for IN only): **HINDUSTAN LEVER LIMITED** [IN/IN]; Hindustan Lever House, 165/166 Backbay Reclamation, Maharashtra, 400 020 Mumbai (IN).

(72) Inventors: **DONOVAN, Robert, Mark**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB). **GREEN, Martin**,

Richard; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB). **TASKER, Maria, Catherine**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB). **YATES, Paula, Rachel**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).

(74) Agents: **MULDER, Cornelis, Willem, Reinier et al.**; Unilever PLC, Patent Department, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/39960 A2

(54) Title: **COSMETIC METHOD OF TREATING SKIN**

(57) Abstract: A cosmetic method for treating aged, wrinkled and/or photodamaged skin is provided through topical application of a composition which comprises 8-prenylnaringenin.

BEST AVAILABLE COPY

- 1 -

COSMETIC METHOD OF TREATING SKIN

This invention relates to a cosmetic method of improving the
5 condition and appearance of skin and to the use of 8-
prenylnaringenin in the preparation of topical compositions
for improving the condition and appearance of skin.

Skin is subject to deterioration through dermatological
10 disorders, environmental abuse (wind, air conditioning,
central heating, etc.) or through the normal aging process
(chronoaging) which may be accelerated by exposure of skin
to sun (photoaging). In recent years the demand for
cosmetic compositions and cosmetic methods for improving the
15 appearance and condition of skin has grown enormously.

Consumers are increasingly seeking "anti-aging" cosmetic
products which treat or delay the visible signs of
chronoaging and photoaging skin such as wrinkles, lines,
20 sagging, hyperpigmentation and age spots.

Consumers also frequently seek other benefits from cosmetic
products in addition to anti-aging. The concept of
"sensitive skin" has also raised the consumer demand for
25 cosmetic products which improve the appearance and condition
of sensitive, dry and/or flaky skin and to soothe red,
and/or irritated skin. Consumers also desire cosmetic
products which treat spots, pimples, blemishes etc.

30 8-prenylnaringenin as a substance is known. For example, in
The Journal of Endocrinology & Metabolism Vol. 83 No. 6,
Milligan et al., "Identification of a potent phytoestrogen
in hops and beer", 8-prenylnaringenin is recognized as being
a potent phytoestrogen. The structure of 8-prenylnaringenin

- 2 -

is also shown in that paper. 8-prenylnaringenin occurs naturally in hops, from which it can be isolated and concentrated.

- 5 We have now surprisingly found further undisclosed properties of 8-prenylnaringenin, which are useful in cosmetic compositions for topical application to skin to provide previously undisclosed skin care benefits.
- 10 We have now found that effective treatment and prevention of normal skin conditions due to chronoaging or photoaging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, may be obtained through the application of cosmetic compositions to the skin which comprise 8-prenylnaringenin
- 15 or derivatives thereof. We have also found that the use of 8-prenylnaringenin in cosmetic compositions advantageously provides further skin benefits in addition to anti-aging such as for soothing sensitive and/or irritated skin.
- 20 In a first aspect the invention comprises a topical composition for application to the human skin comprising an effective amount of 8-prenylnaringenin.

According to a further aspect of the present invention there

25 is a method of providing at least one cosmetic skin care benefit selected from: treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin; soothing irritated, red and/or sensitive skin; improving

30 skin texture, smoothness and/or firmness; the method comprising applying to the skin a topical composition comprising 8-prenylnaringenin and/or derivatives thereof.

- 3 -

The present invention also encompasses the use of 8-prenylnaringenin and/or derivatives thereof in the preparation of a topical composition for providing at least one skin care benefit selected from treating/preventing
5 wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin; soothing irritated, red and/or sensitive skin; improving skin texture, smoothness and/or firmness.

10 Another aspect of the present invention provides 8-prenylnaringenin for use in the treatment of wrinkling, sagging, aged and/or photodamaged skin; for boosting collagen deposition in skin; for boosting decorin production in skin; for soothing irritated, red and/or sensitive skin;
15 and for improving skin texture, smoothness and/or firmness.

The inventive methods and use of 8-prenylnaringenin thus provide anti-aging benefits which result in the promotion of smooth and supple skin with improved elasticity and a
20 reduced or delayed appearance of wrinkles and aged skin, with improved skin colour. A general improvement in the appearance, texture and condition, in particular with respect to the radiance, clarity, and general youthful appearance of skin may be achieved. The inventive methods
25 and uses are also beneficial for soothing and calming sensitive and/or irritated skin. Thus the inventive methods advantageously provide a wide range of skin care benefits.

These benefits might include improved hydration, texture/tone, smoothness, silkiness, firmness,
30 strength/resilience and radiance.

The term "treating" as used herein includes within its scope reducing, delaying and/or preventing the above mentioned

- 4 -

skin conditions such as wrinkled, aged, photodamaged, and/or irritated skin and generally enhancing the quality of skin and improving its appearance and texture by preventing or reducing wrinkling and increasing flexibility, firmness, smoothness, suppleness and elasticity of the skin. The cosmetic methods and the uses of 8-prenylnaringenin and/or derivatives according to the invention may be useful for treating skin which is already in a wrinkled, aged, photodamaged and irritated condition or for treating youthful skin to prevent or reduce those aforementioned deteriorative changes due to the normal aging/photo aging process.

The invention also includes derivatives of the free molecule which thus comprise 8-prenylnaringenin moieties.

15

The active 8-prenylnaringenin to be employed in accordance with the present invention is present in the topical composition in an effective amount. Normally the total amount of the active is present in an amount between 0.0001% and 50% by weight of the composition. More preferably the amount is from 0.001% to 10% and most preferably from 0.01% to 1% in order to maximize benefits at a minimum cost.

The composition used according to the invention also comprises a dermatologically/cosmetically acceptable vehicle to act as a dilutant, dispersant or carrier for the active. The vehicle may comprise materials commonly employed in skin care products such as water, liquid or solid emollients, silicone oils, emulsifiers, solvents, humectants, thickeners, powders, propellants and the like.

The vehicle will usually form from 5% to 99.9%, preferably from 25% to 80% by weight of the composition, and can, in

- 5 -

the absence of other cosmetic adjuncts, form the balance of the composition.

- Besides the active, 8-prenylnaringenin, other specific skin-
5 benefit actives such as sunscreens, skin lightening agents
and skin tanning agents may also be included. The vehicle
may also further include adjuncts such as perfumes,
opacifiers, preservatives, colourants and buffers.
- 10 To prepare the topical composition used in the method of the
present invention, the usual manner for preparing skin care
products may be employed. The active components are
generally incorporated in a dermatologically acceptable
carrier in conventional manner. The active components can
15 suitably first be dissolved or dispersed in a portion of the
water or another solvent or liquid to be incorporated in the
composition. The preferred compositions are oil-in-water or
water-in-oil emulsions.
- 20 The composition may be in the form of conventional skin-care
products such as a cream, gel or lotion or the like. The
composition can also be in the form of a so-called "wash-
off" product e.g. a bath or shower gel, possibly containing
a delivery system for the actives to promote adherence to
25 the skin during rinsing. Most preferably the product is a
"leave-on" product; a product to be applied to the skin
without a deliberate rinsing step soon after its application
to the skin.
- 30 The composition may packaged in any suitable manner such as
in a jar, a bottle, tube, roll-ball, or the like, in the
conventional manner.

- 6 -

- The method of the present invention may be carried out one or more times daily to the skin which requires treatment. The improvement in skin appearance will usually become visible after 1 to 3 months, depending on skin condition,
- 5 the concentration of the active components used in the inventive method, the amount of composition used and the frequency with which it is applied. In general, a small quantity of the composition, for example from 0.1 to 5 ml is applied to the skin from a suitable container or applicator
- 10 and spread over and/or rubbed into the skin using the hands or fingers or a suitable device. A rinsing step may optionally follow depending on whether the composition is formulated as a "leave-on" or a "rinse-off" product.
- 15 In order that the present invention may be more readily understood, the following examples are given, by way of illustration only, with reference to the accompanying drawings, in which:
- 20 - Figure 1 shows the effect of 8-prenylnaringenin on decorin synthesis;
- Figure 2 shows the effect of 8-prenylnaringenin on procollagen synthesis; and
- Figure 3 shows the effect of 8-prenylnaringenin on
- 25 the reduction of PGE2 expression.

EXAMPLES

- 30 The first example demonstrates the anti-aging benefits of 8-prenylnaringenin.

- 7 -

It is known from our co-pending European application no. 99908956.8 that topical retinoic acid treatments can be used to cause upregulation of procollagen I and decorin in vivo. To this end, the passages under the heading "Identification
5 of procollagen I and decorin upregulation in skin in vivo following topical retinoic acid treatment for comparative purposes" in that application are incorporated herein in their entirety.

10 Example 1

Procedure For Measuring Procollagen-I and Decorin Synthesis
In Human Dermal Fibroblasts

15 Preparation of Dermal Fibroblast Conditioned Medium

Primary human foreskin fibroblasts at passage 2 (P2) were seeded into 12-well plates at 10000 cells/cm² and maintained for 24 hours in an atmosphere of 5% carbon dioxide and 4%
20 oxygen in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal calf serum. After this time the cells were washed with serum free DMEM and then incubated in fresh serum free DMEM for a further 60 hours. The fibroblast monolayers were then washed again with serum
25 free DMEM. Test reagents and vehicle controls were added to the cells in triplicate in a final volume of 0.4ml/well fresh serum free DMEM and incubated for a further 24 hours. This fibroblast conditioned medium was either analyzed immediately or snap frozen in liquid nitrogen and stored at
30 -70°C for future analysis. The cells were then counted and data from the dot-blot analysis subsequently standardized to cell number.

Dot Blot Assay for Procollagen-I and Decorin Protein in
Dermal Fibroblast Conditioned Medium

Samples of conditioned medium from dermal fibroblasts
5 treated with vehicle (as a control) or test reagents were
supplemented with 20mM dithiothreitol (1:10 dilution of
200mM stock solution) and 0.1% sodium dodecylsulphate (1:100
dilution of 10% stock solution), mixed well and then
incubated at 75°C for 2 minutes. A standard for the assay
10 was generated by serial dilution of neat fibroblast
conditioned medium from fibroblasts seeded at 10000 cells/cm²
in a 175cm² flask and maintained in serum free DMEM as
described above.

15 Assay samples were subsequently applied in triplicate to a
pre-wetted sheet of Immobilon-P transfer membrane using the
96-well Bio-Dot Apparatus from Bio-Rad as described in the
manufacturer's guidelines. Approximately 200µl of medium
was applied per well. The medium was allowed to filter
20 through the membrane under gravity (30 minutes) after which
the membrane was washed twice with PBS (200µl). These PBS
washes were allowed to filter through the membrane under
gravity (2x15 minutes). The Bio-Dot apparatus was then
attached to a vacuum manifold and a third and final PBS wash
25 carried out under suction. The apparatus was disassembled,
the membrane removed and quickly cut as required before
being placed in blocking buffer overnight at 4°C.

Membranes prepared for decorin analysis were blocked with 3%
30 (w/v) BSA/ 0.1% (v/v) Tween 20 in PBS, whilst those for
procollagen-I analysis were blocked with 5% (w/v) non fat
dried milk powder/ 0.05% Tween 20 in PBS. The following
day, the membranes were probed with 1:10000 dilution of

- 9 -

primary antibodies to either human procollagen-I (MAB1912; rat monoclonal; Chemicon Int. Inc., Temecula, CA) or human decorin (rabbit polyclonal; Biogenesis) for 2 hours at room temperature. The membranes were subsequently washed with
5 TBS/ 0.05% Tween 20 (3 x 5 minutes) and then incubated with 1:1000 dilution of ^{125}I -conjugated anti-rat or anti-rabbit F(ab')₂ fragments (Amersham) as required for 1 hour at room temperature.

10 Following this the Immobilon strips were again washed with TBS/Tween 20 (3 x 5 minutes) before being allowed to dry in air at room temperature. The dried membranes were wrapped in cellophane and exposed to a Molecular Dynamics storage phosphor screen for 16-18 hours. At the end of this time the
15 exposed screen was scanned by a phosphorimager (Molecular Dynamics Phosphorimager SF) using ImageQuant™ software. Dot intensity was assessed by computer-assisted image analysis using the quantification tools in ImageQuant™, standardized to cell number and the effects of various test reagents on
20 decorin and procollagen-I synthesis were determined relative to a vehicle treated control value of 100 arbitrary units.

TESTS

25 The results of the assays are shown graphically in figures 1 and 2. In order to normalize the results the effects of the test substance was determined relative to a vehicle treated control value of 100 arbitrary units.

30 For comparison, a trial was performed with retinoic acid to assess its effect on decorin synthesis in human dermal fibroblasts.

- 10 -

The results in figures 1 and 2 indicate that 8-prenylnaringenin significantly upregulates the synthesis of both procollagen-I and decorin in human dermal fibroblasts as compared to the control.

5

The level of decorin in skin is associated with improved condition and appearance of skin. Increasing the level of decorin in skin is important for controlled and correct deposition of collagen in skin which is associated with many skin benefits such as wrinkle effacement and dermal repair of photodamaged skin.

The comparative trial with retinoic acid (1 μ m) showed an upregulation of decorin, 138 \pm 14 (p=0.035, n=4), as determined relative to a vehicle treated control value of 100 arbitrary units. Surprisingly, the data thus further indicates that the magnitude of the upregulation of and decorin synthesis in human dermal fibroblasts effected by exceeds that of the bench-mark anti-aging dermal repair active, retinoic acid.

Further comparative tests were conducted to compare the upregulation of Procollagen I and Decorin using 8-prenylnaringenin and other known estrogens, or phytoestrogens.

The same protocols as described above were used in the tests.

Initially, results were obtained for the known estrogens/phytoestrogens in media which contained Phenol Red (itself having estrogenic activity). The tests were then repeated for 8-prenylnaringenin and the known

- 11 -

estrogens/phytoestrogens in media which was free of Phenol Red. The results are set out below in Tables 1 and 2.

Table 1

- 5 Percentage increases in the levels of Procollagen I and Decorin secreted from human fibroblasts cultured in media containing phenol red.

Active at 1 uM (in media containing phenol red)	Procollagen I	Decorin
17- β -Estradiol	107.7	121
Resveratrol	102.1	113.1
Daidzein	118	98.9
Genistein	124	114

- 10 Data are presented in arbitrary units relative to a vehicle control value of 100.

Table 2

- 15 Percentage increases in the levels of Procollagen I and Decorin secreted from human fibroblasts cultured in media minus phenol red.

Active at 1 uM (phenol red-free media)	Procollagen I	Decorin
8-Prenylnaringenin	350	800
17- β -Estradiol	170	130
Daidzein	152	252
Genistein	200	240

- 20 Data are presented in arbitrary units relative to a vehicle control value of 100.

- 12 -

From the above test results, it is clear that 8-Prenylnaringenin is a much better inducer of Procollagen I and Decorin than other known estrogens or phytoestrogens themselves. Without wishing to be bound by theory, it is
5 believed that 8-Prenylnaringenin is not acting like a phytoestrogen, but may be promoting the synthesis of the two repair markers through another molecular pathway.

Example 2

10 Fibroblast PGE2 Assay

The following example demonstrates that 8-prenylnarigenin can effectively reduce the basal levels of prostaglandin E₂ (PGE2) secreted by fibroblasts in vitro.

Primary human foreskin fibroblasts at passage 2 (P2) were
15 seeded into 96-well plates at 10000 cells/well and maintained for 24 hours in an atmosphere of 5% carbon dioxide in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal calf serum. 8-prenylnaringenin was dissolved in ethanol was added to fresh cell media
20 (final concentration 1% EtOH in DMEM, supplemented with 10% foetal calf serum) and added to the cells in the wells in triplicate and incubated for a further 24 hours. Phorbol myristate acetate (PMA) (Sigma) was added to the media and the cells incubated for a further 24 hours. PMA acts as the
25 stressor that induces oxidative stress and inflammatory responses in cells. The fibroblasts/media were then analyzed as described below immediately or snap frozen in liquid nitrogen and stored at -70°C for future analysis.

- 13 -

Prostaglandin E2 (PGE2) assay

Volumes of 50µl culture medium were taken for PGE2 assay after gently shaking the culture plate. PGE2 levels in the medium were determined with a Biotrak PGE2 immunoassay kit (Amersham, UK). The assay is based on the competition between unlabelled PGE2 in the sample and a fixed quantity of horseradish peroxidase labeled PGE2 for a limited amount of fixed PGE2 specific antibody. Concentrations of unlabelled sample PGE 2 are determined according to a standard curve, which was obtained at the same time.

The anti-inflammatory potential of the test compounds was assessed by the ability of the compounds to reduce the basal levels of secreted PGE₂ as compared to the control. The results that were obtained are shown in Figure 3.

PGE₂ is a well known mediator of inflammation in the skin see Greaves et al "Prostaglandins, leukotrienes, phospholipase, platelet activating factor and cytokines: an integrated approach to inflammation of human skin", Arch. Dermatol. Res. (1988) 280 [suppl]: 533-541. The results indicated that fibroblasts treated with 8-prenylnaringenin produce less of the pro-inflammatory prostaglandin PGE2, thereby reducing the inflammatory potential of the skin.

Example 3

The formulation below describes an oil in water cream suitable for the methods and uses according to the present invention. The percentages indicated are by weight of the composition.

	wt%
Mineral Oil	4
8-prenylnaringenin	1.15
Brij 56*	4
Alfol 16RD*	4
Triethanolamine	0.75
Butane-1,3-diol	3
Xanthan gum	0.3
Perfume	Qs
Butylated hydroxy toluene	0.01
Water	To 100

*Brij 56 is cetyl alcohol POE (10)

Alfol 16RD is cetyl alcohol

5 Example 4

The formulation below describes an emulsion cream according to the present invention.

- 15 -

FULL CHEMICAL NAME OR CTFA NAME	TRADE NAME	WT. %
8-prenylnaingenin		2.0
disodium EDTA	Sequesterene Na2	0.05
Magnesium aluminium silicate	Veegum Ultra	0.6
methyl paraben	Methyl Paraben	0.15
Simethicone	DC Antifoam Emulsion	0.01
butylene glycol 1,3	Butylene Glycol 1,3	3.0
Hydroxyethylcellulose	Natrosol 250HHR	0.5
Glycerine, USP	Glycerine USP	2.0
xanthan gum	Keltrol 1000	0.2
Triethanolamine	Triethanolamine (99%)	1.2
stearic acid	Pristerene 4911	3.0
propyl paraben NF	Propylparaben NF	0.1
glyceryl hydrostearate	Naturechem GMHS	1.5
stearyl alcohol	Lanette 18 DEO	1.5
Isostearyl palmitate	Protachem ISP	6.0
C12-15 alcohols octanoate	Hetester FAO	3.0
Dimethicone	Silicone Fluid 200 (50cts)	1.0
Cholesterol NF	Cholesterol NF	0.5
sorbitan stearate	Sorbitan Stearate	1.0
Butylated hydroxytoluene	Embanox BHT	0.05
Tocopheryl acetate	Vitamin E Acetate	0.1
PEG-100 stearate	Myrj 59	2.0
sodium stearyl lactylate	Pationic SSL	0.5
Hydroxycaprylic acid	Hydroxycaprylic Acid	0.1
retinyl palmitate	Vitamin A Palmitate	0.06
alpha-bisabolol	Alpha-bisabolol	0.2
water, DI		q.s. to 100

Both the above topical compositions of example 3 and 4 may provide an effective cosmetic treatment to improve the appearance of wrinkled, aged, photo-damaged, and/or irritated skin, when applied to skin that has deteriorated through the aging or photoageing or when applied to youthful skin to help prevent or delay such deteriorative changes. The compositions can be processed in conventional manner.

CLAIMS

1. A topical composition comprising:
5
 (a) an effective amount of 8-prenylnaringenin; and
 (b) a dermatologically acceptable vehicle.
2. A topical composition according to claim 1 wherein the
10 8-prenylnaringenin is present at a level of 0.001 to 1.0% by weight of the composition.
3. A cosmetic method of providing at least one cosmetic
15 skin care benefit selected from: treating/preventing wrinkling, sagging, dry, aged and/or photodamaged skin; boosting/maintaining collagen levels in skin; boosting/maintaining decorin levels in skin; improving skin texture, smoothness and/or firmness; and soothing irritated, red and/or sensitive skin; the method
20 comprising applying to the skin a topical composition as claimed in claim 1 or 2.
4. Use of a topical composition as claimed in any of claim
25 1 or claim 2 for providing at least one skin care benefit selected from treating/preventing wrinkling, sagging, aged, dry, and/or photodamaged skin; boosting/maintaining collagen levels in skin; boosting/maintaining decorin levels in skin; soothing irritated, red and/or sensitive skin; improving skin
30 texture, and smoothness and/or firmness.

1/2

Fig.1.






Fig.2.



2/2

Fig.3.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/039960 A3

(51) International Patent Classification⁷: **A61K 7/48**

(21) International Application Number: **PCT/EP01/12732**

(22) International Filing Date:
2 November 2001 (02.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0027769.9 14 November 2000 (14.11.2000) GB

(71) Applicant (for AE, AG, AU, BB, BZ, CA, CY, GB, GD, GH, GM, IE, IL, KE, LC, LK, LS, MN, MW, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW only): **UNILEVER PLC** [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB).

(71) Applicant (for AL, AM, AT, AZ, BA, BE, BF, BG, BJ, BR, BY, CF, CG, CH, CI, CM, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GA, GE, GN, GQ, GR, GW, HR, HU, ID, IS, IT, JP, KG, KP, KR, KZ, LR, LT, LU, LV, MA, MC, MD, MG, MK, ML, MR, MX, MZ, NE, NL, NO, PH, PL, PT, RO, RU, SE, SI, SK, SN, TD, TG, TJ, TM, TR, UA, UZ, VN, YU only): **UNILEVER NV** [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).

(71) Applicant (for IN only): **HINDUSTAN LEVER LIMITED** [IN/IN]; Hindustan Lever House, 165/166 Backbay Reclamation, Maharashtra, 400 020 Mumbai (IN).

(72) Inventors: **DONOVAN, Robert, Mark**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB). **GREEN, Martin, Richard**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).

TASKER, Maria, Catherine; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB). **YATES, Paula, Rachel**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).

(74) Agents: **MULDER, Cornelis, Willem, Reinier et al.**; Unilever PLC, Patent Department, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
25 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/039960 A3

(54) Title: COSMETIC METHOD OF TREATING SKIN

(57) Abstract: A cosmetic method for treating aged, wrinkled and/or photodamaged skin is provided through topical application of a composition which comprises 8-prenylnaringenin.

INTERNATIONAL SEARCH REPORT

International Application No

PO 01/12732

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 1996, no. 10, 31 October 1996 (1996-10-31) & JP 08 165238 A (SANKYO CO LTD), 25 June 1996 (1996-06-25) abstract ---	1
Y	DATABASE WPI Section Ch, Week 197713 Derwent Publications Ltd., London, GB; Class D21, AN 1977-22800Y XP002198821 & JP 52 021339 A (MATSUI T), 17 February 1977 (1977-02-17) abstract --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

14 May 2002

Date of mailing of the international search report

28/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Voyiazoglou, D

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 2732

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MILLIGAN S R ET AL: "The endocrine activities of 8-prenylnaringenin and related hop (<i>Humulus lupulus</i> L.) flavonoids" BIOSIS, XP002185291 the whole document	1
A	--- PATENT ABSTRACTS OF JAPAN vol. 1999, no. 14, 22 December 1999 (1999-12-22) & JP 11 246387 A (SHISEIDO CO LTD), 14 September 1999 (1999-09-14) abstract	1,3,4
A	--- US 6 071 525 A (KIM JEONG-HA ET AL) 6 June 2000 (2000-06-06) claim 1	1,3,4
A	--- PATENT ABSTRACTS OF JAPAN vol. 015, no. 227 (C-0839), 10 June 1991 (1991-06-10) & JP 03 068518 A (TSUMURA & CO), 25 March 1991 (1991-03-25) abstract	1
A	--- PATENT ABSTRACTS OF JAPAN vol. 015, no. 112 (C-0815), 18 March 1991 (1991-03-18) & JP 03 005423 A (ICHIMARU PHARCOS CO LTD), 11 January 1991 (1991-01-11) abstract	1,3,4
A	--- DE 199 22 287 A (COLETICA LYON) 25 November 1999 (1999-11-25) claims 1,10,14	1,3,4
E	--- EP 1 190 630 A (UNILEVER PLC ;UNILEVER NV (NL)) 27 March 2002 (2002-03-27) claims 1,12 -----	3,4

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

P 01/12732

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 08165238	A	25-06-1996	NONE	
JP 52021339	A	17-02-1977	JP 60050765 B	11-11-1985
JP 11246387	A	14-09-1999	NONE	
US 6071525	A	06-06-2000	KR 253842 B1 JP 11079936 A	01-07-2000 23-03-1999
JP 03068518	A	25-03-1991	NONE	
JP 03005423	A	11-01-1991	NONE	
DE 19922287	A	25-11-1999	FR 2778663 A1 DE 19922287 A1 JP 2000026263 A US 6235294 B1 US 2001031735 A1	19-11-1999 25-11-1999 25-01-2000 22-05-2001 18-10-2001
EP 1190630	A	27-03-2002	EP 1190630 A1	27-03-2002

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)